Skip to main content

Home/ health information/ Group items tagged injections

Rss Feed Group items tagged

Adelaide Hypnosis Matthew Tweedie

NLP and Hypnosis for Fear of Needles and Needle Phobia Adelaide - 1 views

  •  
    Patients with an intense fear of injections who have undergone a session or two of hypnotherapy and NLP will easily overcome their fear. These processes target the unconscious, the imagination, memory, and belief system to unravel your phobia. They will loosen the influence that disproportionate fear has over you. Hypnotherapy and NLP will lessen the body's fight-or-flight reaction to trypanophobia. They also link to your emotional core and release you from this distressing fear.
pharmacybiz

AstraZeneca to stop developing Crohn's disease drug - 0 views

  •  
    British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan. AbbVie will stop funding the drug's development, AstraZeneca said. AbbVie's Skyrizi also treats Crohn's disease.
Rattinan Medical Center

Effective Underarm Odor Treatment in Bangkok: Discover Lasting Solutions - 0 views

  •  
    In this informative blog post, we will delve into the topic of underarm odor treatment in Bangkok, discussing the causes, available options, and how our skilled team of professionals can help you find lasting relief. At Rattinan Medical Center, we prioritize your well-being and strive to provide exceptional care tailored to your individual needs.
pharmacybiz

Smart deals saved taxpayers £1.2b on medicines procurement - 0 views

  •  
    The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price. The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel disease and psoriasis, has accounted for about one third of the savings. After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions, which have the same quality, safety and efficacy of a branded one. Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to aggressive blood cancers. Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality patient care. NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.
robert1488stp

Sclerotherapy Training Courses for Physicians and Nurses in New York City on Jul 08, 20... - 0 views

  •  
    Sclerotherapy Training Courses for Physicians and Nurses is organized by Empire Medical Training and will be held on Jul 08, 2022 at New York Marriott at the Brooklyn Bridge, New York City, New York, United States of America
pharmacybiz

GSK To Get $1.25B To Settle HIV Drug Patent Row With Gilead - 0 views

  •  
    Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.
pharmacybiz

Rowlands New Weight Loss Management Service - 0 views

  •  
    Rowlands pharmacy has launched a new weight management service across its UK network, challenging perceptions around weight loss and providing expert support to those in need. The launch comprises a pilot roll-out across 100 Rowlands branches to increase consideration of pharmacies for weight management-based advice. Commenting on the launch, Nigel Swift, managing director of Rowlands, said: "One of the biggest challenges facing many adults looking to address any weight concerns is knowing where and how to start. Our new weight management service is designed to help all those setting out on a new weight loss journey but also those who have struggled to find a plan that works for them." "Our pharmacy teams offer comprehensive healthcare advice and a variety of weight management products with a friendly approach that naturally puts customers at ease, and we're looking forward to welcoming all those looking to take their first step with us."
« First ‹ Previous 121 - 127 of 127
Showing 20 items per page